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Survivin is a structurally unique member of the inhibi-
tors of apoptosis protein family and is involved in the
control of cell division and inhibition of apoptosis. The
notion that survivin is overexpressed in most human
tumors but absent in normal adult tissues with only a
few exceptions has led to the proposal of survivin as a
promising therapeutic target for novel anticancer thera-
pies. In this context, we generated a hammerhead ribo-
zyme targeting the 30 end of the CUA110 triplet in the
survivin mRNA. Two human melanoma cell lines (JR8
and M14) overexpressing survivin were stably trans-
fected with the pRc/CMV vector carrying the ribo-
zyme sequence. Two polyclonal cell populations proven
to endogenously express ribozyme and characterized
by a markedly lower survivin protein level (^60% and
^50%, respectively) than JR8 and M14 parental cells
were selected for the study. Ribozyme-expressing cells
showed a signi¢cantly (po0.01) increased sensitivity to
c-irradiation (as detected by clonogenic cell survival)
compared to JR8 and M14 cells. Moreover, in the JR8
cell line, the extent of radiation-induced apoptosis
(in terms of percentage of apoptotic nuclei in cells
stained with propidium iodide and level of caspase-3
catalytic activity) was markedly greater in ribozyme-
expressing cells than in parental cells. These results dem-
onstrate for the ¢rst time that attenuation of survivin
expression renders human melanoma cells more sus-
ceptible to c-irradiation. Key words: apoptosis/ionizing
radiation/melanoma/ribozyme/survivin. J Invest Dermatol
120:648 ^654, 2003
M
elanoma is considered to be a chemotherapy-
and radiotherapy-refractory tumor type, even
though the molecular determinants responsible
for such treatment resistance have not yet been
fully elucidated (Serrone and Hersey, 1999). Re-
cent studies, however, have demonstrated that melanoma cells ex-
hibit defects at multiple levels of the program of apoptotic cell
death (Satyamoorthy et al, 2001), including altered death receptor
signaling (Thomas and Hersey, 1998), increased levels of antia-
poptotic proteins belonging to the Bcl-2 family such as Bcl-XL
and Mcl-1 (Tang et al, 1998), inactivation of the apoptosis e¡ector
Apaf-1 (Soengas et al, 2001), and overexpression of members of
the inhibitors of apoptosis protein (IAP) family, such as ML-IAP
(Vucic et al, 2000) and survivin (Grossman et al, 1999). In particu-
lar, survivin expression has been detected in almost all invasive
and metastatic melanomas but not in normal skin melanocytes
(Grossman et al, 1999).
Considering that apoptosis is the major mode of cell kill by
many chemotherapeutic agents and radiation, it appears reason-
able that the inability to undergo programmed cell death is
a major mechanism of the chemoresistance and radioresistance
of melanoma. As a consequence, the genes that control apoptosis
provide interesting new targets for the rational development of
strategies aimed at increasing the susceptibility of melanoma cells
to chemical and physical treatments. Survivin is a structurally
unique IAP family protein that is potentially involved in both
control of cell division and inhibition of apoptosis (Altieri and
Marchisio, 1999). Speci¢cally, its antiapoptotic function is related
to the ability to inhibit caspases (Altieri, 2001). It has been pre-
viously demonstrated by Grossman et al (1999) that transfection
of melanoma cells with survivin antisense was able to increase
the fraction of spontaneous apoptosis. The same research group
reported that the forced expression of a phosphorylation-defective
survivin mutant (Thr34-Ala) in melanoma cell lines, besides
triggering apoptosis, enhanced the level of programmed cell death
induced by in vitro treatment with the chemotherapeutic agent cis-
platin (Grossman et al, 2001a). Such results have recently been con-
¢rmed by our group using a ribozyme-mediated approach to
inhibit survivin expression in a di¡erent melanoma cell line
(Pennati et al, 2002). Speci¢cally, we demonstrated that melanoma
cells engineered to express hammerhead ribozymes targeting dif-
ferent portions of survivin mRNA displayed an enhanced apop-
totic response to cisplatin compared to cells transfected with a
mutant, catalytically inactive ribozyme.
As a possible role of survivin as a molecular determinant of
radiation response in tumor cells has recently been proposed by
Asanuma et al (2000), who reported evidence suggesting that this
protein acts as a constitutive and inducible radioresistance factor
in pancreatic cancer cell lines, in this study we proposed to assess
the e¡ect of attenuation of survivin expression, accomplished
through a ribozyme-mediated strategy, in the response of human
melanoma cells to g-irradiation.
MATERIALS ANDMETHODS
Cell line The JR8 and M14 human melanoma cell lines were maintained
in the logarithmic growth phase at 371C in a 5% CO2 humidi¢ed
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atmosphere using RPMI 1640 (BioWhittaker, Verviers, Belgium)
supplemented with 10% fetal bovine serum, 2 mM L-glutamine, and
0.25% gentamycin. Both cell lines carry a mutation in exon 8 of the p53
gene (Villa et al, 2000).
Design and synthesis of ribozymes and in vitro cleavage reaction
The ribozyme design was performed by an ‘‘in silico’’ approach using the
already described, home-developed computing method (Mercatanti et al,
2002), which predicts the regions of the survivin mRNA endowed with the
most probable conformational accessibility. Many NUH consensus cleavage
triplets (N, any nucleotide; H¼A, C, U) lie within these accessible regions;
therefore they were recognized to be suitable targets for hammerhead
ribozymes. A series of catalytic ribozyme sequences were correspondingly
deduced. The ¢nal analysis accounting for the correct structureactivity
relationship enabled us to select the hammerhead ribozyme addressed to the
CUA110 triplet located on the survivin mRNA. The ribozyme sequence,
50 -CUUGAAUGCUGAUGAGGCCGAAAGGCCGAAAGAGAUG-30 (RZ),
was synthesized by in vitro transcription. A mutant ribozyme (mutRZ)
was also designed and synthesized by deleting the G12 from the catalytic
core (as indicated by the circled letter in Fig 1A) in order to obtain a negative
control. Single-stranded synthetic DNA oligonucleotides encoding active
and mutant ribozymes were obtained from M-Medical (Florence, Italy).
The oligonucleotide sequences were the following: RZþ , 50 -AGCTTCT-
TGAATGCTGATGAGGCCGAAAGGCCGAAAGAGATGT-30; RZ, 50 -
CTAGACATCTCTTTCGGCCTTTCGGCCTCATCAGCATTCAAGA-30;
mutRZþ , 50 -AGCTTCTTGAATGCTGATGAGGCCGAAAGGCCAAA-
GAGATGT-30; and mutRZ, 50 -CTAGACATCTCTTTGGCCTTTCGGC-
CTCATCAGCATTCAAGA-30. Annealing of the complementary oligo-
nucleotides produced two fragments with Hind III and Xba I protruding
ends. Each fragment was inserted into the pRc/CMV vector (Promega,
Madison,WI), which had been previously digested with Hind III and Xba I
restriction enzymes.The presence and the correct orientation of the inserts was
veri¢ed by DNA sequencing (AmpliCycleTM, Perkin Elmer-Roche Molecular
System, Branchburg, NJ). The resulting plasmids were named pRcRZ and
pRcmutRZ. To obtain the active and the mutant ribozymes, both plasmids
were linearized with Xba I. Twenty micrograms of the resulting linear
templates were transcribed in vitro in 0.2 ml of a reaction mixture composed
of 260 U recombinant RNAsin ribonuclease inhibitor (Promega), 0.25 mM
each of ribonucleotide triphosphates, 5 mM dithiothreitol, 1transcription
bu¡er (40 mM TrisHCl, pH 8, 8 mM MgCl2, 2 mM spermidine), and 200
U T7 RNA polymerase (Takara, Shuzo, Otsu Shiga, Japan). The reaction
mixtures were incubated for 2 h at 371C and then treated with 20 U RQ1
RNase-free DNase (Promega) for 20 min at 371C. The products were
extracted with phenol/chloroform saturated with 10 mM Tris, 1 mM
ethylenediamine tetraacetic acid (EDTA), pH 4.5, precipitated with 100%
isopropyl alcohol/3 M ammonium acetate, pH 5.5, washed with 70% pre-
chilled ethanol, dried by speed vacuum, and resuspended in bidistilled water.
The concentration and the purity of the transcription products were assessed
byA260 and A260/A280 spectrophotometric measurement, respectively.The tran-
scription products of expected size were then veri¢ed by gel electrophoresis.
To obtain the internally labeled RNA substrate, pCIsurvivin plasmid
(which was made by introducing the 1619 bp full-length human survivin
cDNA into the EcoRI site of the mammalian pCI Neo vector) was
linearized with Sty I restriction enzyme. The resulting linear template was
transcribed in vitro in the presence of [a-32P]cytidine triphosphate (10 mCi per
ml, 800 Ci per mmol, Amersham International, Buckinghamshire), using
the riboprobe in vitro transcription system (Promega) according to the
manufacturer’s instructions. The reaction product was puri¢ed and the
transcription product of expected size was veri¢ed as described above. 32P-
substrate RNA (10 nM) was mixed with increasing concentrations of
ribozyme in 50 mM TrisHCl, pH 7.5. The mixtures were heated for 5 min
at 901C, cooled at 371C, and then incubated in the presence of 50 mMMgCl2.
The cleavage reactions were performed at 371C for 120 min. Reactions were
stopped by adding an equal volume of stop solution (95% formamide, 20 mM
EDTA, 0.05% bromophenol blue, 0.02% xylene cyanol FF). Products were
resolved on 5% polyacrylamide/7 M urea gel and the results were quanti¢ed
by densitometric analysis.
Transfection of cells with the ribozyme expression vectors
DOTAP (N-1-(2,3-dioleoyloxypropyl)-N,N,N-trimethylammoniummethyl
sulfate, Boehringer Mannheim, Mannheim, Germany) mediated trans-
fection of JR8 and M14 cells was performed according to the manu-
facturer’s instructions. Brie£y, cells previously seeded at a density yielding
approximately 50% con£uency at the time of transfection were transfected
with 5 mg of pRcRZ vector (or pRcmutRZ vector) that had been
complexed with 30 mg of DOTAP. Twenty-four hours after transfection
the culture medium containing the DOTAP/DNA mixture was replaced
by a selection medium containing G418 to a ¢nal concentration of 2 mg
per ml for JR8 and 1.5 mg per ml for M14. The transfected cells were
exposed to G418 for 1 mo for the selection of di¡erent cellular clones.
Two polyclonal populations expressing the active ribozyme (JR8RZ and
M14RZ cells) and two polyclonal populations expressing the mutant
ribozyme (JR8mutRZ and M14mutRZ cells) were selected for the study.
Reverse transcription polymerase chain reaction (RT-PCR)
analysis of ribozyme expression Total RNA isolated from the
transfectants and parental JR8 cell line was reverse transcribed using a
GeneAmp RNA PCR core kit (Perkin Elmer) according to the
manufacturer’s instructions. To analyze ribozyme (RZ and mutRZ)
expression the resultant cDNA was ampli¢ed using T7 and SP6 primers
(M-Medical) and by performing 30 cycles of PCR (at 951C for 1 min,
471C for 1 min, and 721C for 1 min), followed by a 7 min extension step
at 721C. PCR products were veri¢ed by agarose gel electrophoresis.Vectors
pRcRZ and pRcmutRZ were used during PCR ampli¢cation as control
for the correct fragment size.
Figure1. Ribozyme structure and in vitro catalytic activity. (A)
Schematic representation of base pairing of the RZ ribozyme with its
RNA target site obtained from survivin mRNA.The cleavage site is indi-
cated by an arrow. The mutant ribozyme mutRZ, which was used as con-
trol throughout the study, was obtained by deleting the G12 from the
catalytic core of the active ribozyme. (B) In vitro cleavage of the 362-mer
32P-RNA substrate (10 nM) by RZ into the cleavage products (236- and
126-mer). The synthetic 32P substrate was incubated with 10^1000 nM RZ
or with 1000 nM mutRZ for 120 min at 371C. In the control sample (BL),
32P substrate RNAwas incubated without the ribozyme. The reaction pro-
ducts were resolved on 5% polyacrylamide/7 M urea gel and visualized by
autoradiography.
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Western immunoblotting For protein analysis, total cellular lysates
were separated on a 15% sodium dodecyl sulfate polyacrylamide gel and
transferred to nitrocellulose. The ¢lters were blocked in phosphate-
bu¡ered saline with 5% skim milk and then incubated overnight with
primary antibodies speci¢c for survivin (Novus Biologicals, Littleton,
U.K.), Bcl-2, Bax (Santa Cruz Biotechnology, Santa Cruz, CA), caspase-3,
caspase-8, and caspase-9 (BD Transduction Laboratories, San Diego, CA).
The ¢lters were then incubated with the secondary peroxidase-linked
whole antibodies (Amersham Biosciences Europe, Freiburg, Germany).
Bound antibodies were detected using the enhanced chemiluminescence
Western blotting detection system (Amersham Biosciences). An anti-
proliferating cell nuclear antigen monoclonal antibody (Santa Cruz
Biotechnology) was used on each blot to ensure equal loading of protein
on the gel. Results were quanti¢ed by densitometric analysis.
Irradiation Exponentially growing cells were harvested with trypsin:
EDTA (0.005:0.02%) and irradiated at room temperature using a 137-Cs g-
irradiator (IBL-437, Oris, France) at a dose rate of 7.2 Gy per min.
Immediately after irradiation or 72 h after irradiation, the cells were
processed for colony formation or apoptosis experiments, respectively, as
outlined below.
Colony formation assay After treatment with 1^10 Gy ionizing
radiation, JR8 and M14 cells were plated at appropriate concentrations in
plastic dishes and incubated at 371C in an atmosphere of 5% CO2 and
95% air for 10 d. Colonies consisting of at least 50 cells were stained with
crystal violet in 70% vol/vol ethanol/water and counted under the
microscope. The colony-forming e⁄ciency was calculated from the
number of colonies counted and the number of morphologically intact
single cells seeded. The surviving fractions of treated cells relative to
unirradiated cells were determined, and the data were ¢tted to the
multitarget single-hit model of cell inactivation: S/S0¼1[1 ^ exp(^D/
D0)]
n, where S/S0 is the surviving fraction and D is the dose (Gy). The
parameters n and D0 were calculated using ELMAT software (kindly
provided by Dr. Benassi, Regina Elena Cancer Institute, Rome, Italy).
Triplicate determinations of each radiation dose were performed and
an intra-experiment average was calculated. The points shown on the
clonogenic survival curves are the inter-experiment averages (and
their relative standard deviations) calculated from at least three intra-
experiment averages.
Apoptosis analysis Cells exposed to g-irradiation (2, 6, and 10 Gy) were
incubated at 371C for 48 or 72 h and then scored for nuclear morphology
of apoptosis (chromatin condensation, DNA fragmentation) by labeling
with a solution containing 50 mg per ml propidium iodide, 50 mg per ml
RNAse, and 0.05% Nonidet P-40. After staining, the slides were examined
using £uorescence microscopy. The percentage of cells with an apoptotic
nuclear morphology was determined by scoring at least 500 cells in each
sample.
Caspase-3, caspase-8, and caspase-9 proteolytic processing was analyzed
byWestern blot analysis in cells harvested 72 h after exposure to 10 Gy, as
described above. In the same cellular samples caspase-3 catalytic activity
was determined by the use of the Caspase-3 Assay kit (Pharmingen, San
Diego, CA). Brie£y, total protein and the £uorogenic substrate N-Acetyl-
Asp-Glu-Val-aldehyde (Ac-DEVD-AMC) were mixed for 1 h at 371C in
the presence or absence of the caspase inhibitor Ac-DEVD-CHO.
Hydrolysis of the substrate was monitored by spectro£uorometry at 440 nm.
RESULTS
In vitro functional analysis of the ribozyme As the ¢rst step
of our study we veri¢ed the catalytic potential of the RZ
ribozyme on an internally 32P-labeled synthetic 362-nucleotide
RNA substrate obtained by cloning a portion of the human
survivin mRNA. Figure 1(A) shows a schematic representation
of the RZ ribozyme annealed to its RNA substrate (the cleavage
site is indicated by an arrow). Experiments performed by
incubating 10 nM of labeled RNA substrate with increasing
concentrations (from 10 to 1000 nM) of the RZ ribozyme for
120 min at 371C (Fig 1B) resulted in the accumulation of the
expected cleavage products of 236 and 126 nucleotides, res-
pectively. The e⁄ciency of cleavage was dependent on the sub-
strate:ribozyme ratio, with the cleavage products being detectable
at a ratio of 1:10. As expected, the mutRZ ribozyme, carrying a
mutation in the catalytic core of the RZ ribozyme, was not able
to induce any cleavage in the synthetic RNA (Fig 1B).
Ribozyme-mediated attenuation of survivin expression in
JR8 melanoma cells In a further step of the study the JR8
human melanoma cell line overexpressing survivin was
transfected with pRcRZ and pRcmutRZ vectors containing the
sequence coding for the active RZ ribozyme and the catalytically
inactive mutRZ ribozyme, respectively. The transfectants were
treated with G418 for 1 mo and the G418-resistant clones were
selected and screened for survivin expression by Western
blotting. To rule out the possibility that attenuation of survivin
expression was simply due to clonal divergence, we used two
polyclonal populations of transfectants proven to endogenously
express the active (JR8RZ cells) or the mutant (JR8mutRZ
cells) ribozyme (Fig 2A). JR8RZ cells were characterized by a
markedly lower survivin protein level (^60%) than JR8 parental
cells, whereas no reduction in survivin expression was observed
in JR8mutRZ cells (Fig 2B). No appreciable di¡erences were
found among the di¡erent melanoma cell lines in the expression
Figure 2. Ribozyme and survivin expression in JR8 melanoma cell
clones. (A) Ribozyme expression was detected by RT-PCR in JR8 paren-
tal cells and cell clones transfected with the active ribozyme (JR8RZ cells)
or with the mutant ribozyme (JR8mutRZ cells). Lanes pRcRZ and
pRcmutRZ indicate plasmids used as controls for the size of each fragment
during PCR ampli¢cation. (B) A representative Western blotting experi-
ment illustrating the expression of survivin and other apoptosis-related
proteins in JR8, JR8RZ, and JR8mutRZ cells. Proliferating cell nuclear
antigen was used as control for loading.
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of other proteins involved in the control of apoptosis, such as Bcl-
2 and Bax (Fig 2B).
Ribozyme-mediated survivin inhibition sensitizes JR8
melanoma cells to c-irradiation To determine whether the
level of survivin expression is associated with the radiosensitivity
of melanoma cells, the di¡erent cell lines were analyzed for their
clonogenic cell survival pro¢les after exposure to di¡erent doses
of g-irradiation (Fig 3). Transfection with the active ribozyme
sequence did not appreciably modify the plating e⁄ciency
of JR8RZ cells compared to JR8 and JR8mutRZ cells
(8.7%70.9% vs 9.8%71.0% and 9.6%71.3%, respectively).
A radiation-dose-dependent reduction in cell survival was
observed in all cell lines. Survival curve parameters are reported
inTable I. JR8RZ cells expressing the active ribozyme, however,
showed enhanced radiosensitivity compared to parental cells.
Speci¢cally, the surviving fractions of JR8RZ cells were
Figure 3. Clonogenic cell survival curves obtained after c-irradia-
tion of JR8 (J), JR8RZ (’), and JR8mutRZ () cells. After treat-
ment cells were plated at appropriate concentrations in plastic dishes and
incubated at 371C for 10 d. Colonies consisting of at least 50 cells were
stained with crystal violet and counted under the microscope. Data repre-
sent mean values7SD of three independent experiments.
Table I. Survival curve parameters of melanoma cell lines
Cell lines D0 n SF2
JR8 1.2970.02 4.8370.45 0.6870.03
JR8RZ 1.1570.01 2.3270.16 0.3670.02
JR8mutRZ 1.2770.02 4.1970.38 0.7070.08
M14 1.2170.02 4.2570.44 0.5970.07
M14RZ 1.1070.03 2.6470.30 0.3370.03
M14mutRZ 1.2570.01 3.6470.03 0.5870.04
Data represent mean values7SD of three independent experiments.
Figure 4. Induction of apoptosis in JR8 melanoma cell clones ex-
posed to c-irradiation. (A) Propidium iodide staining of apoptotic
JR8RZ cells at 48 h after exposure to 6 Gy. (B) The percentage of cells
with an apoptotic morphology with respect to the overall population was
assessed by £uorescence microscopy 48 h (empty column) and 72 h (gray
column) after exposure to di¡erent radiation doses. Data represent mean
values7 SD of three independent experiments. (C) Caspase-3 catalytic ac-
tivity was determined by hydrolysis of the £uorogenic substrate N-Acetyl-
Asp-Glu-Val-Asp-aldehyde (Ac-DEVD-AMC) in the presence or absence
of the caspase-3 inhibitor Ac-DEVD-CHO 72 h after exposure to 10 Gy.
Unirradiated control cells, empty column; g-irradiated cells, gray column;
g-irradiated cellsþCHO, black column.
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signi¢cantly (po0.01, Student’s t test) lower than those observed
for JR8 at all radiation doses starting from 2 Gy. Such
radiosensitization seemed to be a consequence of the decreased
survivin levels in cells expressing the active ribozyme rather
than nonspeci¢c e¡ects of the expression vector itself. In fact,
the survival curve obtained after irradiation of JR8mutRZ cells
expressing the catalytically inactive ribozyme was superimposable
on that obtained for irradiated JR8 parental cells (Fig 3).
To investigate whether the increased cytotoxic activity of g-
irradiation observed in the active ribozyme transfectant cells was
mediated by an enhanced susceptibility of cells to undergo
programmed cell death as a consequence of survivin inhibition,
we examined the extent of apoptosis induction in the di¡erent
cell lines 48 and 72 h after exposure to di¡erent radiation doses.
For this purpose the percentage of cells with an apoptotic nuclear
morphology was determined by £uorescence microscopy after
cell staining with propidium iodide and calculated in relation to
the total cell population (Fig 4A). Spontaneous apoptosis was
observed in a small fraction (alwayso2%) of cells in the
di¡erent cell lines, and g-irradiation consistently induced a dose-
dependent increase in the percentage of apoptotic cells in the
di¡erent clones. In JR8RZ cells expressing the active ribozyme,
however, the extent of radiation-induced programmed cell death
was higher than that observed in JR8mutRZ cells expressing the
mutant ribozyme and in JR8 parental cells (Fig 4B). Speci¢cally,
such a di¡erence was statistically signi¢cant at 48 h (po0.05,
Student’s t test) and 72 h (po0.01, Student’s t test) after exposure
to 10 Gy and at 72 h after exposure to 6 Gy (po0.01, Student’s t
test). Processing of caspase-3 to its active subunits of 17 and 19
kDa was observed in all three radiation-treated cell lines (data
not shown). The caspase-3 catalytic activity, however, as assessed
by hydrolysis of the £uorogenic substrate Ac-DEVD-AMC, was
markedly higher in the JR8RZ than in the JR8mutRZ cells and
in JR8 parental cells after 10 Gy exposure (Fig 4C). Moreover, a
reduction in the 46 kDa caspase-9 precursor was consistently
observed in all radiation-treated cell lines. Conversely, no
appreciable variation in the abundance of the 55 kDa caspase-8
precursor was detected between untreated and radiation-treated
cells (data not shown).
E¡ect of ribozyme-mediated inhibition of survivin
expression on the in vitro response of M14 melanoma cells
to c-irradiation To evaluate the e¡ect of survivin down-
regulation in a second human melanoma cell line, we trans-
fected M14 cells (which are characterized by a slightly lower
abundance of survivin protein than JR8 cells) with pRcRZ and
pRcmutRZ expression vectors. Two polyclonal cell populations
endogenously expressing the active (M14RZ cells) or the mutant
(M14mutRZ cells) ribozyme were selected for the study. M14RZ
cells were characterized by a lower (^50%) level of survivin
expression than parental cells, whereas a minimal reduction was
observed in M14mutRZ cells (Fig 5A). When cells were
exposed to g-irradiation, the clonogenic cell surviving fractions
of M14RZ cells were signi¢cantly (po0.05, Student’s t test)
lower than those observed for M14 and M14mutRZ cells at all
radiation doses starting from 2 Gy (Fig 5B,Table I).
DISCUSSION
Ribozymes are small RNA molecules with endonucleolytic ac-
tivity that catalyze the hydrolysis of speci¢c phosphodiester
bonds, resulting in the cleavage of the RNA target sequences
(Lewin and Hauswirth, 2001). These catalytic RNA motifs have
received much attention in view of their potential usefulness for
gene therapy due to their inherent simplicity, small size, and abil-
ity to be incorporated into a variety of £anking sequence motifs
without changing site-speci¢c cleavage capacities. In fact, a num-
ber of studies on experimental human tumor models have
shown the possibility of obtaining e⁄cient inhibition of several
cancer-related genes through the use of ribozymes (Lewin and
Hauswirth, 2001).
In this study we demonstrated the possibility of markedly
attenuating the expression of the antiapoptotic factor survivin
in two human melanoma cell lines by use of the hammerhead
ribozyme RZ targeting exon 1 within survivin mRNA. This
e¡ect was not observed after inactivation of the catalytic core of
the ribozyme (mutRZ), strongly suggesting speci¢c cleavage ac-
tivity in the cell culture experiments. Ribozyme-transfectant
Figure 5. Ribozyme-mediated inhibition of survivin expression
and clonogenic cell survival after c-irradiation in M14 melanoma
cell clones. (A) AWestern blotting experiment illustrating the expression
of survivin in M14, M14RZ, and M14mutRZ cells. Proliferating cell nucle-
ar antigen was used as control for loading. (B) After g-irradiation M14 (J),
M14RZ (’), and M14mutRZ () cells were plated at appropriate concen-
trations in plastic dishes and incubated at 371C for 10 d. Colonies consisting
of at least 50 cells were stained with crystal violet and counted under
the microscope. Data represent mean values7SD of three independent
experiments.
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cells obtained from both cell lines showed increased sensitivity to
g-irradiation with respect to parental cells and cells transfected
with the mutant ribozyme, as demonstrated by a signi¢cantly re-
duced clonogenic cell survival. Speci¢cally, cells expressing the
active ribozyme were characterized by a survival curve with a
reduced shoulder. Such a ¢nding suggests that, in the clinical set-
ting, survivin inhibition could improve tumor sensitivity to
fractionated therapy with multiple low radiation doses. Our
results are in accord with previous evidence obtained in pancrea-
tic carcinoma cell lines showing a direct relationship between the
extent of survivin expression and the degree of in vitro radioresis-
tance (Asanuma et al, 2000). The same authors also showed that
transduction of a dominant-negative mutant survivin gene into
the radioresistant PANC-1pancreatic cancer cells increased their ra-
diation response (Asanuma et al, 2002). Taken together these results
support the hypothesis that survivin is a molecular determinant of
radiation response.
Radiosensitization of ribozyme-expressing JR8 cells was ac-
companied by an enhanced apoptotic response to g-irradiation
and an increased activation of caspase-3, which is consistent with
the recognized function of survivin to counteract apoptosis (Al-
tieri and Marchisio, 1999). In this context Grossman et al (2001b)
recently demonstrated that in transgenic mice that produced sur-
vivin constitutively in epidermal keratinocytes the fraction of
apoptotic cells generated in the epidermis following exposure to
ultraviolet-B irradiation was signi¢cantly reduced. Interestingly,
in JR8 cells expressing the active RZ ribozyme or another ribo-
zyme targeting exon 3 in survivin mRNA, we previously ob-
served an increased apoptotic response to in vitro treatment with
the chemotherapeutic agent cisplatin (Pennati et al, 2002), thus
con¢rming previous evidence that survivin inhibition sensitizes
tumor cells to chemotherapy (Olie et al, 2000; Grossman et al,
2001a; Mesri et al, 2001a).
In contrast to what was previously observed with other survi-
vin inhibitory approaches based on the use of survivin antisense
(Olie et al, 2000) or survivin dominant negative mutant (Gross-
man et al, 1999; 2001a; Mesri et al, 2001a), in our melanoma cell
system survivin downregulation did not have any appreciable ef-
fect on the cells’ proliferative potential and did not increase the
rate of spontaneous apoptosis. Other antiapoptotic factors, such
as Bcl-2, which are strongly expressed in JR8 cells, might contri-
bute to prevent programmed cell death in this tumor model.
When JR8 cells previously exposed for 48 h to 3 mM of
the Bcl-2 antisense oligonucleotide G3139 (which reduced by
50% the endogenous expression of the Bcl-2 protein) were
g-irradiated, however, no signi¢cant variation in their radiosensi-
tivity pro¢le was observed. Such a ¢nding indicates that this anti-
apoptotic factor does not play a major role in determining the
radiation response of these cells (unpublished data).
It should be stressed that in JR8 cells survivin expression was
attenuated but not completely abrogated. Possibly inhibition
below a certain threshold is insu⁄cient to cause a pro-apoptotic
e¡ect. Interestingly, and in keeping with this hypothesis, when
we transduced DU145 human prostate cancer cells with a Molo-
ney-based retroviral vector carrying the catalytic sequence of the
ribozyme RZ, we were able to select a ribozyme-expressing
clone characterized by almost complete abrogation of survivin
expression and showing a markedly higher level of spontaneous
apoptosis than control culture expressing the catalytically inactive
ribozyme (Pennati et al, manuscript in preparation).
In recent years, studies in which the expression of speci¢c
genes was manipulated have not only led to a better understand-
ing of the molecular basis of radiosensitivity but also provided
clues as to how we can intervene to make tumor cells speci¢cally
more sensitive to radiation (Begg andVens, 2001). Such speci¢city
for tumor tissue can only be obtained by exploiting a basic di¡er-
ence between normal and malignant cells. Recent reports have
documented that the combination of ionizing radiation and ade-
noviral p53 gene therapy was able to enhance the e⁄cacy of
radiotherapy in p53-mutated and p53-null cancer cells (Li et al,
1999). Similarly, farnesyltransferase inhibitors have been shown
to selectively increase the radiosensitivity of tumor cells carrying
a mutated ras gene (Bernhard et al, 1998). Again, enhancement
of the in vitro radiation response of tumor cells overexpressing
the epidermal growth factor receptor (EGFR) was obtained
with di¡erent approaches based on the use of antibodies directed
against the extracellular ligand-binding domain of EGFR (Huang
et al, 1999) or adenovirus-mediated overexpression of dominant
negative EGFR (Lammering et al, 2001).
Here we report for the ¢rst time the possibility of positively
modulating the in vitro radiation sensitivity of human tumor cells
and of restoring their susceptibility to programmed cell death in-
duced by g-irradiation through downregulation of survivin ex-
pression. Targeting survivin is particularly attractive because of
its relatively selective expression in tumor cells (Altieri, 2001).
Moreover, the notion that survivin plays a crucial role also in tu-
mor angiogenesis (Mesri et al, 2001b) suggests that survivin tar-
geting can increase the overall tumor response to radiation
treatment not only through direct interference with the apoptotic
pathways in cancer cells but also by favoring the apoptotic invo-
lution of newly formed tumor vasculature. Considering the mul-
titude of events involved in the response to ionizing radiation
damage, however, it is reasonable to presume that approaches
based on the simultaneous targeting of genes on di¡erent path-
ways would have a greater impact on the ¢nal outcome of the
radiation exposure in tumor cells than the modulation of a single
factor as we did in this study.
In conclusion, the results obtained by us with the ribozyme-
mediated approach in melanoma cells extend and corroborate
earlier evidence indicating survivin as a molecular determinant
of radiation response in tumor cells and suggest a possible
strategy to enhance the sensitivity pro¢le of radiation-refractory
human malignancies.
The study was supported in part by a grant from MIUR-CNR, Special project
‘‘Oncology’’. Marzia Pennati was supported by a fellowship from FIRC.We thank
Barbara Canova for editorial assistance.
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